哮喘合并不同类型持续气流受限患者的临床特征与预后
该前瞻性研究纳入288例合并持续气流受限的哮喘患者,分为PAL-A组141例和ACO组147例,比较两组临床特征及预后。ACO组男性、吸烟、肺气肿比例更高,肺功能及2型炎症指标更低,重度急性发作和肺炎风险更高;两组危险因素不同。
要点
- ACO组较PAL-A组重度急性发作和肺炎风险更高。
- 重度哮喘是两组重度急性发作的共同危险因素。
- 近1年肺炎≥1次是两组肺炎的共同危险因素。
核心结论
- 哮喘合并不同原因所致持续气流受限的患者临床特征及预后存在差异,个体化治疗策略有待探讨。
研究设计与样本
- 前瞻性收集2020年1月至2024年12月北京同仁医院呼吸与危重症医学科288例合并持续气流受限的哮喘患者,男170例、女118例,年龄(63.30±9.19)岁。
- 根据临床及影像学特征分为PAL型哮喘(PAL-A)组147例和哮喘合并慢阻肺病(ACO)组141例,随访6~60个月。
主要发现
- ACO组男性、高血压、冠心病、糖尿病、肺气肿比例及年龄、吸烟指数高于PAL-A组,变应性鼻炎、鼻息肉比例及FEV1占预计值%、DLCO占预计值%、外周血嗜酸性粒细胞百分比、IgE、FeNO低于PAL-A组。
- ACO组近1年哮喘重度急性发作≥1次比例为61.0%(86/141)高于PAL-A组的47.6%(70/147),χ2=5.19,P=0.023。
- ACO组近1年肺炎≥1次比例为53.9%(76/141)高于PAL-A组的31.3%(46/147),χ2=15.07,P<0.001。
- Log-rank检验显示ACO组重度急性发作和肺炎风险较高,χ2分别为11.08和30.20,均P<0.001。
关键数值与推荐
- ACO与年龄(OR=1.10,95%CI:1.032~1.173)、吸烟指数(OR=1.13,95%CI:1.088~1.175)、肺气肿(OR=22.62,95%CI:7.948~64.388)正相关。
- ACO与IgE(OR=1.00,95%CI:0.997~1.000)、FEV1占预计值%(OR=0.96,95%CI:0.929~0.996)、DLCO占预计值%(OR=0.97,95%CI:0.933~0.998)、鼻息肉(OR=0.34,95%CI:0.115~0.977)负相关。
- PAL-A组重度急性发作危险因素:重度哮喘(RR=3.03,95%CI:1.606~5.713)、低FEV1占预计值%(RR=0.97,95%CI:0.950~0.990)、影像学支气管扩张(RR=2.59,95%CI:1.276~5.267)。
- ACO组重度急性发作危险因素:重度哮喘(RR=2.00,95%CI:1.165~3.435)、特异质(RR=1.84,95%CI:1.046~3.238)、低DLCO占预计值%(RR=0.98,95%CI:0.960~0.995)。
- PAL-A组肺炎危险因素:近1年肺炎≥1次(RR=4.00,95%CI:1.525~10.480)、影像学支气管扩张(RR=6.45,95%CI:1.458~28.547);ACO组:重度哮喘(RR=3.15,95%CI:1.724~5.746)、近1年肺炎≥1次(RR=4.98,95%CI:2.445~10.154)、冠心病史(RR=2.19,95%CI:1.186~4.054)。
临床怎么用
- 对合并持续气流受限的哮喘患者应区分PAL-A与ACO,ACO患者需关注更高的重度急性发作和肺炎风险。
- 根据不同的危险因素(如重度哮喘、支气管扩张、特异质、冠心病史等)进行个体化评估与随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To compare the clinical characteristics and prognosis of patients with asthma combined with different types of persistent airflow limitation (PAL). Methods: We prospectively collected the clinical data of 288 asthma patients with PAL treated in the Department of Respiratory Medicine of Beijing Tongren Hospital from January 2020 to December 2024, including 170 males and 118 females, aged (63.30±9.19) years. The patients were divided into the PAL type asthma (PAL-A) group (141 patients) and the asthma-chronic obstructive pulmonary disease overlap (ACO) group (147 patients) based on clinical and imaging characteristics. General demographics, pulmonary function, blood routine tests, and serological results were compared between the two groups. All patients were followed up for 6 to 60 months, and were compared the risk of severe acute exacerbation (SAE) of asthma episodes as well as pneumonia. Statistical analysis was conducted using SPSS 22.0 software. Results: Compared with the PAL-A group, the ACO group had a higher proportion of males,≥1 severe exacerbation of asthma in the last 12 months [61.0%(86/141) vs. 47.6%(70/147), χ2=5.19, P=0.023],≥1 pneumonia in the last 12 months [53.9%(76/141) vs.31.3%(46/147), χ2=15.07, P<0.001], emphysema, hypertension, coronary heart disease, and diabetes, as well as older age and higher smoking index; while the FEV1% predicted, DLCO% predicted, peripheral blood eosinophil percentage, total immunoglobulin E (IgE), fractional exhaled nitric oxide (FeNO), and proportions of allergic rhinitis and nasal polyps were lower. Logistic regression analysis showed that the ACO occurrence was positively correlated with age(OR=1.10, 95%CI: 1.032-1.173), smoking index(OR=1.13, 95%CI: 1.088-1.175), and emphysema(OR=22.62, 95%CI: 7.948-64.388), and negatively correlated with total IgE(OR=1.00, 95%CI: 0.997-1.000), FEV1% predicted(OR=0.96, 95%CI: 0.929-0.996), DLCO% predicted(OR=0.97, 95%CI: 0.933-0.998), and nasal polyps(OR=0.34, 95%CI: 0.115-0.977). Log-rank test results indicated higher risks of SAE (Log-rank χ2=11.08, P<0.001) and pneumonia (Log-rank χ2=30.20, P<0.001) in the ACO group. Cox regression analysis revealed that severe asthma(RR=3.03, 95%CI: 1.606-5.713), impaired FEV1% predicted(RR=0.97, 95%CI: 0.950-0.990), and bronchiectasis in HRCT(RR=2.59, 95%CI: 1.276-5.267) were risk factors for SAE in the PAL-A group, whereas severe asthma(RR=2.00, 95%CI: 1.165-3.435), atopy(RR=1.84, 95%CI: 1.046-3.238), and impaired DLCO% (RR=0.98, 95%CI: 0.960-0.995) predicted were risk factors for SAE in the ACO group; meanwhile,≥1 pneumonia in the last 12 months (RR=4.00, 95%CI: 1.525-10.480)and bronchiectasis in HRCT(RR=6.45, 95%CI: 1.458-28.547) were risk factors for pneumonia in the PAL-A group, whereas severe asthma(RR=3.15, 95%CI: 1.724-5.746),≥1 pneumonia in the last 12 months(RR=4.98, 95%CI: 2.445-10.154) and coronary heart disease history(RR=2.19, 95%CI: 1.186-4.054) were risk factors for pneumonia in the ACO group. Conclusion: Among asthma patients, the clinical characteristics and prognosis vary according to the underlying causes of PAL, highlighting the need for further exploration of individualized treatment strategies. 目的: 对比支气管哮喘(简称哮喘)合并不同类型持续气流受限(PAL)患者的临床特征及预后。 方法: 前瞻性收集2020年1月至2024年12月北京同仁医院呼吸与危重症医学科288例合并PAL哮喘患者的临床资料,其中男170例,女118例,年龄(63.30±9.19)岁。根据临床及影像学特征分为PAL型哮喘(PAL-A)组147例和哮喘合并慢阻肺病(ACO)组141例,对比两组患者一般资料、肺功能、血常规及血清学等结果差异;对两组患者进行随访,随访时间6~60个月,对比两组患者哮喘重度急性发作(SAE)和肺炎发生的风险差异。采用SPSS 22.0软件进行统计学分析。 结果: 与PAL-A组相比,ACO组男性、高血压、冠心病、糖尿病、近1年哮喘SAE≥1次[61.0%(86/141)比47.6%(70/147),χ2=5.19,P=0.023]、近1年肺炎≥1次[53.9%(76/141)比31.3%(46/147),χ2=15.07,P<0.001]、肺气肿的比例及年龄、吸烟指数较高,合并变应性鼻炎、鼻息肉的比例及FEV1占预计值%、DLCO占预计值%、外周血嗜酸性粒细胞百分比、免疫球蛋白E(IgE)、呼出气一氧化氮浓度较低。logistic回归分析显示,ACO的存在与年龄(OR=1.10,95%CI:1.032~1.173)、吸烟指数(OR=1.13,95%CI:1.088~1.175)、肺气肿(OR=22.62,95%CI:7.948~64.388)呈正相关,与IgE(OR=1.00,95%CI:0.997~1.000)、FEV1占预计值%(OR=0.96,95%CI:0.929~0.996)、DLCO占预计值%(OR=0.97,95%CI:0.933~0.998)、鼻息肉(OR=0.34,95%CI:0.115~0.977)呈负相关。Log-rank检验结果显示,ACO组SAE和肺炎发生的风险较高(Log-rank χ2=11.08和30.20,均P<0.001)。Cox回归分析显示,重度哮喘是两组患者发生SAE的共同危险因素(PAL-A组RR=3.03,95%CI:1.606~5.713;ACO组 RR=2.00,95%CI:1.165~3.435),低FEV1占预计值%(RR=0.97,95%CI:0.950~0.990)和影像学支气管扩张(RR=2.59,95%CI:1.276~5.267)是PAL-A组、特异质(RR=1.84,95%CI:1.046~3.238)和低DLCO占预计值%(RR=0.98,95%CI:0.960~0.995)是ACO组发生SAE的危险因素;近1年肺炎≥1次是两组患者发生肺炎的共同危险因素(PAL-A组RR=4.00,95%CI:1.525~10.480;ACO组RR=4.98,95%CI:2.445~10.154);影像学支气管扩张(RR=6.45,95%CI:1.458~28.547)是PAL-A组、重度哮喘(RR=3.15,95%CI:1.724~5.746)和冠心病史(RR=2.19,95%CI:1.186~4.054)是ACO组发生肺炎的危险因素。 结论: 对于哮喘患者,不同原因所致持续气流受限的临床特征及预后存在差异,个体化的治疗策略有待探讨。.
引用
- Sheng, Yao, Liu, et al. [Clinical characteristics and prognosis of patients with asthma complicated with different types of persistent airflow limitation]. Zhonghua Jie He He Hu Xi Za Zhi. 2026. PMID: 41629092. doi:10.3760/cma.j.cn112147-20250813-00487
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。